Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

sustained-release mitomycin C hydrogel formulation UGN-103

A sustained-release (SR) reverse thermal (RT) hydrogel formulation containing a lyophilized form of the antineoplastic antibiotic mitomycin C (MMC), with potential antineoplastic activity. Upon intravesical instillation of the SR MMC hydrogel formulation UGN-103, the liquid converts into gel form and conforms to the bladder wall, allowing MMC to be deposited locally in the bladder to prevent the excretion of this chemotherapeutic agent via urinary flow. In turn, MMC alkylates DNA, and produces interstrand DNA cross-links, thereby inhibiting DNA synthesis resulting in inhibition of tumor cell proliferation. Due to its reverse thermal-gelation properties, this gel is able to stay in a liquid state at cold temperatures, and undergoes transition to a water-soluble gel at body temperature. This allows for increased accumulation of MMC locally in the upper urinary tract which leads to increased efficacy compared to standard intravesical delivery of MMC for bladder cancer.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:mitomycin C SR hydrogel formulation UGN-103
SR MMC hydrogel formulation UGN-103
Code name:UGN 103
UGN-103
UGN103
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search